CER Daily Newsfeed

Value Viewpoint: October 10, 2025

(10/10, Kimberly Westrich, LinkedIN) comments “...On Thursday, the Health Economics Methods Advisory (HEMA) group released its Draft Report: Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies, along with a plain language summary...As HEMA’s first public release, the draft report offers insights into HEMA’s priorities and perspective. Although presented as an exploration of expanding the benefits considered in health technology assessment (HTA), the draft report could be read as a defense of current or past HTA practices. It does not clearly position any additional benefits for inclusion, and guidance on incorporating the patient voice is unclear.” Full

Real-World Evidence Complements Randomized Clinical Trial Data in Colorectal Cancer

(10/10, Courtney Flaherty, OncLive) reports “In the above video, 3 leading experts in colorectal cancer (CRC) discussed how real-world evidence could help address unmet needs for patient populations typically ineligible for or underrepresented in clinical trials, clarify differences in treatment decision-making in everyday practice vs academic settings, and inform sequencing strategies for approved agents.” Full

Intravenous Ketamine Outperforms Intranasal Esketamine in Depression

(10/10, Medscape) reports “Twice-weekly intravenous (IV) ketamine over a 4- to 5-week induction period for severe treatment-resistant depression (TRD) was associated with a faster and greater reduction in symptoms than intranasal (IN) esketamine, although overall tolerability was similar, a new retrospective study showed.” Full